Results 11 to 20 of about 42,544 (264)

HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis. [PDF]

PLoS ONE, 2017
BackgroundHBeAg seroconversion is an important intermediate outcome in HBeAg-positive chronic hepatitis B (CHB) patients. This study aimed to compare the effect of nucleos(t)ide analogs (NAs) on HBeAg seroconversion in treating CHB with lamivudine ...
Tongjing Xing, Hongtao Xu, Lin Cao, Maocong Ye   +3 more
doaj   +3 more sources

Serological Markers Hbsag and Hbeag in Chronic Hepatitis B Carriers and their Correlation with Viral DNA by Polymerase Chain Reaction [PDF]

Journal of Pure and Applied Microbiology, 2019
Hepatitis B is the most widespread and important type of viral hepatitis which may become chronic and lead to complications like cirrhosis and hepatocellular carcinoma.
Rasika Borgaonkar, Praveen R. Shahapur
doaj   +2 more sources

Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs [PDF]

Infection and Drug Resistance, 2018
Background Patients with chronic hepatitis B virus (HBV) infection who are hepatitis B virus e antigen (HBeAg) positive are increasingly being treated with nucleos(t)ide analogs (NUCs).
S. Cai, Zhandong Li, Tao Yu, Muye Xia, Jie Peng   +4 more
semanticscholar   +2 more sources

HBeAg mediates inflammatory functions of macrophages by TLR2 contributing to hepatic fibrosis

BMC Medicine, 2021
Background We and others have confirmed activation of macrophages plays a critical role in liver injury and fibrogenesis during HBV infection. And we have also proved HBeAg can obviously induce the production of macrophage inflammatory cytokines compared
Xiaoyu Xie, Huanran Lv, Chenxi Liu, Xiaonan Su, Zhen Yu, Shouyang Song, Hongjun Bian, Miaomiao Tian, Chengyong Qin, Jianni Qi, Qiang Zhu   +10 more
doaj   +2 more sources

Differential Plasma MicroRNA Profiles in HBeAg Positive and HBeAg Negative Children with Chronic Hepatitis B [PDF]

PLoS ONE, 2013
Children chronically infected with hepatitis B virus (HBV) are at high risk of progressive liver disease. However, no treatment is available that is consistently effective in curing chronic hepatitis B (CHB) in children. Improved understanding of the natural course of disease is warranted.
Winther, Thilde Nordmann, Bang-Berthelsen, Claus Heiner, Heiberg, Ida Louise, Pociot, Flemming, Hogh, Birthe   +4 more
openaire   +6 more sources

Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. [PDF]

New England Journal of Medicine, 2004
BACKGROUND: Available treatments for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically continued indefinitely, a strategy ...
P. Marcellin, G. Lau, F. Bonino, P. Farci, S. Hadziyannis, R. Jin, Zhi-meng Lu, T. Piratvisuth, G. Germanidis, C. Yurdaydın, M. Diago, S. Gurel, M. Lai, P. Button, N. Pluck   +14 more
semanticscholar   +2 more sources

HBeAg negative chronic hepatitis B in South Asia [PDF]

Bhutan Health Journal, 2016
Chronic Hepatitis B (CHB) infection has an intermediate prevalence rate in South Asian countries, except for Nepal and Sri Lanka where it has a low rate. HBeAg negative CHB infection has been found to be more pronounced in this part of the world.
Ananta Shrestha, Thupten Kelsang Lama, Sudhamshu KC, Dilip Sharma, Sandip Khadka, Guru Prasad Dhakal, Birendra Prasad Gupta   +6 more
doaj   +3 more sources

Different interventional criteria for chronic hepatitis B pregnant women with HBeAg(+) or HBeAg(-)

Medicine, 2018
The seroprevalence of hepatitis B virus (HBV) and its impact on pregnancy outcomes of women from Shaanxi Province (China) was assessed. Risk factors for mother-to-child transmission (MTCT) were evaluated based on HBV-related seroprevalence data.Viral markers and biochemical parameters were assessed in HBsAg-positive mothers and their infants out of 13 ...
Chen, Tianyan, Wang, Jing, Qiu, Hongtao, Yu, Qiang, Yan, Taotao, Qi, Caijing, Cao, Furong, Tian, Zhen, Guo, Dandan, Yao, Naijuan, Yang, Yuan, He, Yingli, Zhao, Yingren, Liu, Jinfeng   +13 more
openaire   +3 more sources

A multicenter randomized-controlled trial of nucleos(t)ide analogue cessation in HBeAg-negative chronic hepatitis B.

Journal of Hepatology, 2023
BACKGROUND & AIMS Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B, as functional cure (loss of HBsAg) is rarely achieved.
F. van Boemmel, K. Stein, R. Heyne, J. Petersen, P. Buggisch, C. Berg, S. Zeuzem, A. Stallmach, M. Sprinzl, E. Schott, A. Pathil-Warth, U. von Arnim, V. Keitel, J. Lohmeyer, K. Simon, C. Trautwein, A. Trein, D. Hüppe, M. Cornberg, F. Lammert, P. Ingiliz, R. Zachoval, H. Hinrichsen, A. Zipprich, H. Klinker, J. Schulze zur Wiesch, A. Schmiedeknecht, O. Brosteanu, T. Berg   +28 more
semanticscholar   +1 more source

Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8+ T and NK cell function

Cellular & Molecular Immunology, 2021
Pegylated interferon-alpha (PegIFNα) therapy has limited effectiveness in hepatitis B e-antigen (HBeAg)-positive chronic hepatitis B (CHB) patients. However, the mechanism underlying this failure is poorly understood.
Zhen Xun, Jinpiao Lin, Qingqing Yu, Can Liu, Jin-lan Huang, Hongyan Shang, Jianhui Guo, Y. Ye, Wennan Wu, Yongbin Zeng, Songhang Wu, Siyi Xu, Tianbin Chen, J. Chen, Q. Ou   +14 more
semanticscholar   +1 more source